303 related articles for article (PubMed ID: 12542895)
21. Autoantibodies against low-density lipoprotein and atherogenic potential of blood.
Kacharava AG; Tertov VV; Orekhov AN
Ann Med; 1993 Dec; 25(6):551-5. PubMed ID: 8292305
[TBL] [Abstract][Full Text] [Related]
22. Serum level of IgG autoantibodies against oxidized low density lipoproteins and lag-phase of serum oxidation in coronary heart disease--inverse correlation.
Bakalova R; Zhelev Z; Goudev A; Ribarov S; Nachev C
Gen Physiol Biophys; 1999 Mar; 18(1):87-97. PubMed ID: 10378123
[TBL] [Abstract][Full Text] [Related]
23. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease.
Mudd JO; Borlaug BA; Johnston PV; Kral BG; Rouf R; Blumenthal RS; Kwiterovich PO
J Am Coll Cardiol; 2007 Oct; 50(18):1735-41. PubMed ID: 17964036
[TBL] [Abstract][Full Text] [Related]
24. A tertiary care hospital-based study of conventional risk factors including lipid profile in proven coronary artery disease.
Goel PK; Bharti BB; Pandey CM; Singh U; Tewari S; Kapoor A; Garg N; Sinha N
Indian Heart J; 2003; 55(3):234-40. PubMed ID: 14560932
[TBL] [Abstract][Full Text] [Related]
25. Impact of postprandial lipaemia on low-density lipoprotein (LDL) size and oxidized LDL in patients with coronary artery disease.
Granér M; Kahri J; Nakano T; Sarna SJ; Nieminen MS; Syvänne M; Taskinen MR
Eur J Clin Invest; 2006 Nov; 36(11):764-70. PubMed ID: 17032343
[TBL] [Abstract][Full Text] [Related]
26. PON1, a new biomarker of cardiovascular disease, is low in patients with systemic vasculitis.
Quéméneur T; Martin-Nizard F; Kandoussi A; Kyndt X; Vanhille P; Hachulla E; Hatron PY; Fruchart JC; Duriez P; Lambert M
Semin Arthritis Rheum; 2007 Dec; 37(3):149-55. PubMed ID: 17512573
[TBL] [Abstract][Full Text] [Related]
27. Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients.
Boumaiza I; Omezzine A; Rejeb J; Rebhi L; Kalboussi N; Ben Rejeb N; Nabli N; Ben Abdelaziz A; Boughazala E; Bouslama A
Metab Syndr Relat Disord; 2010 Dec; 8(6):515-22. PubMed ID: 20715933
[TBL] [Abstract][Full Text] [Related]
28. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation.
Santos AO; Fonseca FA; Fischer SM; Monteiro CM; Brandão SA; Póvoa RM; Bombig MT; Carvalho AC; Monteiro AM; Ramos E; Gidlund M; Figueiredo Neto AM; Izar MC
Clin Chim Acta; 2009 Aug; 406(1-2):113-8. PubMed ID: 19523463
[TBL] [Abstract][Full Text] [Related]
29. Autoantibodies against oxidized low-density lipoprotein and C-reactive protein are associated with diabetes and myocardial infarction in women.
Dotevall A; Hulthe J; Rosengren A; Wiklund O; Wilhelmsen L
Clin Sci (Lond); 2001 Nov; 101(5):523-31. PubMed ID: 11672458
[TBL] [Abstract][Full Text] [Related]
30. Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events.
Tsimikas S; Brilakis ES; Lennon RJ; Miller ER; Witztum JL; McConnell JP; Kornman KS; Berger PB
J Lipid Res; 2007 Feb; 48(2):425-33. PubMed ID: 17093289
[TBL] [Abstract][Full Text] [Related]
31. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
Holvoet P; Perez G; Zhao Z; Brouwers E; Bernar H; Collen D
J Clin Invest; 1995 Jun; 95(6):2611-9. PubMed ID: 7769103
[TBL] [Abstract][Full Text] [Related]
32. Minimally modified electronegative LDL and its autoantibodies in acute and chronic coronary syndromes.
Oliveira JA; Sevanian A; Rodrigues RJ; Apolinário E; Abdalla DS
Clin Biochem; 2006 Jul; 39(7):708-14. PubMed ID: 16782081
[TBL] [Abstract][Full Text] [Related]
33. The level of malondialdehyde-modified LDL and LDL immune complexes in patients with rheumatoid arthritis.
Wang J; Hu B; Meng Y; Zhang C; Li K; Hui C
Clin Biochem; 2009 Sep; 42(13-14):1352-7. PubMed ID: 19501077
[TBL] [Abstract][Full Text] [Related]
34. The relationship of TFPI, Lp(a), and oxidized LDL antibody levels in patients with coronary artery disease.
Bilgen D; Sönmez H; Ekmekçi H; Ulutin T; Oztürk Z; Kökoğlu E; Bayram C; Soner A; Domaniç N
Clin Biochem; 2005 Jan; 38(1):92-6. PubMed ID: 15607324
[TBL] [Abstract][Full Text] [Related]
35. Oxidation of apolipoprotein B-containing lipoproteins and serum paraoxonase/arylesterase activities in major depressive disorder.
Sarandol A; Sarandol E; Eker SS; Karaagac EU; Hizli BZ; Dirican M; Kirli S
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Aug; 30(6):1103-8. PubMed ID: 16716479
[TBL] [Abstract][Full Text] [Related]
36. Antibody titer against malondialdehyde-modified LDL compares with HDL cholesterol concentration in identifying angiographically verified coronary artery disease. Comparison of tests by ROC analysis.
Rontu R; Metso S; Jaakkola O; Nikkilä M; Jokela H; Lehtimäki T
Clin Chem Lab Med; 2005; 43(4):357-60. PubMed ID: 15899649
[TBL] [Abstract][Full Text] [Related]
37. Differences in human antioxidized LDL autoantibodies in patients with stable and unstable angina.
Fernandes JL; Orford JL; Garcia C; Coelho OR; Gidlund M; Blotta MH
J Autoimmun; 2004 Dec; 23(4):345-52. PubMed ID: 15571928
[TBL] [Abstract][Full Text] [Related]
38. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial).
Goldenberg I; Benderly M; Sidi R; Boyko V; Tenenbaum A; Tanne D; Behar S
Am J Cardiol; 2009 Jan; 103(1):41-5. PubMed ID: 19101227
[TBL] [Abstract][Full Text] [Related]
39. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
40. Accumulation of apoE-enriched triglyceride-rich lipoproteins in patients with coronary artery disease.
Barbagallo CM; Rizzo M; Noto D; Frasheri A; Pernice V; Rubino A; Pieri D; Pinto V; Cefalù AB; Giordano C; Notarbartolo A; Averna MR
Metabolism; 2006 May; 55(5):662-8. PubMed ID: 16631444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
